Study of Olaparib and Durvalumab in IDH-Mutated Solid Tumors

NCT03991832 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Glioma
Cholangiocarcinoma
Solid Tumor
IDH Mutation

Interventions

DRUG: Olaparib
DRUG: Durvalumab

Sponsor

University Health Network, Toronto